SpringerLink
Log in

Die Rolle inkretinbasierter Therapien bei NAFLD/NASH

GLP-1-RA senken Inflammationsmarker in klinischen Studien

  • Fortbildung
  • Published:
CardioVasc Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284-96

  2. Nauck MA, Quast DR, Wefers J et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102

  3. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes - Teilpublikation der Langfassung, 2. Auflage. Version 1. 2021. https://doi.org/10.6101/AZQ/000475. Accessed 18 Sept 2022

  4. Pedrosa MR, Franco DR, Gieremek HW et al. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Curr Atheroscler Rep. 2022; https://doi.org/10.1007/s11883-022-01062-2

  5. Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2022; https://doi.org/10.1210/endrev/bnac018

  6. Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2022;107:29-38

  7. Vanderheiden A, Harrison LB, Warshauer JT et al. Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. J Clin Endocrinol Metab. 2016;101:1798-806

  8. Feng W, Gao C, Bi Y et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017;9:800-9

  9. Petit JM, Cercueil JP, Loffroy R et al. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab. 2017;102:407-15

  10. Frøssing S, Nylander M, Chabanova E et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes Metab. 2018;20:215-8

  11. Kuchay MS, Krishan S, Mishra SK et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020;63:2434-45

  12. Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-90

  13. Newsome PN, Buchholtz K, Cusi K et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384:1113-24

  14. Roeb E, Canbay A, Bantel H et al. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) - April 2022 - AWMF-Registernummer: 021-025. Z Gastroenterol. 2022;60:1346-421

  15. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21:169. https://doi.org/10.1186/s12933-022-01604-7

Download references

Author information

Authors and Affiliations

  1. Med. Klinik IV/Klinik f. Diabetologie, Endokrinologie, Universitätsklinikum Tübingen, Otfried-Müller-Straße 10, 72076, Tübingen, Deutschland

    Baptist Gallwitz

Authors
  1. Baptist Gallwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baptist Gallwitz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gallwitz, B. Die Rolle inkretinbasierter Therapien bei NAFLD/NASH. CV 22, 24–27 (2022). https://doi.org/10.1007/s15027-022-2927-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-022-2927-z

Search

Navigation